** Stu's Views & M.S. News **
This is a Blog for those Affected by Multiple Sclerosis. We Are Dedicated to the Global Collection, Dissemination and Distribution of MS Information.
ABOUT this BLOG and How to use it
WELCOME to Stu's Views & MS News, a product of MS Views and News, a Not-for-Profit 501(c3) organization. Founded in 2008. We provide educational Multiple Sclerosis information via live seminars and via the internet.
Key-Note: Our live MS educational seminars average approx 65 people per educational program and we average more than (18) programs per year.
Register at our website to receive our globally transmitted Multiple Sclerosis e-newsletter, currently being received in more than (90) Countries. Visit MS Views and News.org
On this blog -View all to the left and all to the right. Scroll through entire page, to find information that could EMPOWER You. At the Bottom of this page, see informational videos.
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Monday, June 17, 2013
Living with Advancing Multiple Sclerosis: Series Overview (10-part Video series)
| Reactions: |
Study looks at family influences in multiple sclerosis
Sometimes multiple sclerosis (MS) runs in families. It has not been clear how similar the disease is between family members, however. MS is very variable in its symptoms and progression. Researchers at the University of Cambridge report a study which shows how the course of MS varies within families.
..
| Reactions: |
Stem Cells Hold Potential to Repair Immune Responses in MS Patients (Video)

| Reactions: |
Mother diagnosed with MS and facing life in a wheelchair is cured - after she discovered her symptoms were due to a TICK BITE
Julia Marshall-Wessendorf, 37, was diagnosed with multiple sclerosis in 2010
An MRI scan showed lesions on her brain and spinal cord consistent with MS
Was on expensive drug regime and thought she faced future in a wheelchair
Developed other symptoms inconsistent with MS so did some research
Went to doctor and asked for test for tick-borne Lyme disease
It came back positive so she was treated with a simple course of antibiotics
Read more: http://www.dailymail.co.uk/health/article-2343062/Mother-diagnosed-MS-facing-life-wheelchair-cured--discovered-symptoms-TICK-BITE.html#ixzz2WVhjHhzo
Follow us: @MailOnline on Twitter | DailyMail on Facebook
..
| Reactions: |
Thursday, June 13, 2013
UPCOMING MS Views & News - education programs in Florida
Treatment Options, Adhereance, Symptom Management and Visual problems with MS
Treatment Strategies& Symptom Management in Multiple Sclerosis
Multiple Sclerosis Treatment Options, MS Relapse, Symptom Management, Adherence and the Visual Concerns of MS
Adherence, MS Relapse, MRI, Treatment and Symptom Strategies AND THE IMPACT of MS on the Family - in Tampa, Fl.
Treatment Options, Symptoms Management and Adaptive Exercise for MS - in Ormond Beach, Fl.
AUGUST programs to soon be announced.
..
.
| Reactions: |
New imaging technique holds promise for speeding MS research

Download Full Size Image
..
| Reactions: |
Wednesday, June 12, 2013
Treat and Prevent a Multiple Sclerosis Flare-Up
Symptoms of a True Flare
- You develop a new symptom of MS. For example, you’ve never had vision problems before, and suddenly you can’t see clearly out of your left eye.
- A regular problem gets worse. Maybe you’ve had some numbness in your left leg before, but now you can’t feel anything below your knee.
- Your symptoms last for 24 hours or longer. A relapse means a change in your brain, called a lesion. "If a symptom lasts less than 24 hours, it’s something transient that’s not related to a new lesion," says Edward Fox, MD, PhD, director of the MS Clinic of Central Texas.
- Symptoms level off after a while and stop getting worse.
MS False Alarms and What Causes Them
- Alcohol. One drink can worsen coordination for some people.
- Cold or flu. Fever or an infection can feel like a flare-up. MS symptoms go away fairly quickly after the illness passes.
- Heat or cold. Hot or humid weather, exercise, hot showers, and sunbathing can trigger symptoms such as blurred vision. Cold can bring on spastic muscles.
- Poor sleep position. Morning numbness that goes away after you shake it out is not likely to be a flare-up, even if it happens every day. You just slept wrong.
Ordinary Fatigue or MS Relapse?
How to Prevent a Flare
- Closely track your symptoms. "If you notice subtle breakthrough events, it may mean that your medication isn’t working for you, and we need to make a change," says Cohen.
- Stop smoking. "Smoking is extremely bad for MS," says Fox. Smokers lose brain tissue much faster than those who don't smoke, he says. Ask your doctor about nicotine patches, gums, or lozenges. They don't seem to cause the same damage as tobacco and can help you kick the habit.
- Live healthy. Eat a balanced diet. Exercise most days of the week. Try to lower the stress in your life. You'll be healthier, which may make it easier to manage MS. Working out and relaxation may also help control your symptoms.
Treatments
- Steroids. If you've lost some vision or suddenly can't walk, your doctor may suggest this type of drug. "Steroids [help] make the patient better faster," says Mark Keegan, MD, of the Mayo Clinic. You'll need an IV for three to five days, or a lot of pills over a few days.
- Physical therapy. These precise exercises help you recover the use of a hand or leg. Fox says PT works especially well while you're taking steroids. The combination helps you get back to your normal strength and motion.
- Plasma exchange. This may help treat a severe flare-up -- for example, you were walking fine and now you can’t walk at all -- when high-dose steroids aren’t working.
- Watchful waiting. When symptoms are annoying but not severe, like a little numbness in your hand, you may choose to just watch them closely and see if they get better.
..
REMAIN up to date with MS News and Education
| Reactions: |
Multiple Sclerosis and Stress Management
What Are the Warning Signs of Stress?
- Emotional warning signs include anger, an inability to concentrate, unproductive worry, sadness, and frequent mood swings.
- Physical warning signs include stooped posture, sweaty palms, chronic fatigue, and weight gain or loss.
- Behavioral warning signs include overreacting, acting on impulse, using alcohol or drugs, and withdrawing from relationships.
What Can I Do to Reduce Stress?
- Keep a positive attitude.
- Accept that there are events that you cannot control.
- Be assertive instead of aggressive. Assert your feelings, opinions, or beliefs instead of becoming angry, combative, or passive.
- Learn relaxation techniques (see below).
- Exercise regularly. Your body can fight stress better when it is fit. Talk to your doctor before starting an exercise program.
- Eat well-balanced meals.
- Rest and sleep. Your body needs time to recover from stressful events.
- Don't rely on alcohol or drugs to reduce stress.
How Can I Learn to Relax?
- A quiet location that is free of distractions
- A comfortable body position; sit or recline on a chair or sofa.
- A good state of mind.; try to block out worries and distracting thoughts.
..
REMAIN up to date with MS News and Education
| Reactions: |
NPR News: A Delay In Relief From Copays For Costly Drugs
by MICHELLE ANDREWS
June 11, 2013
For people with a chronic or serious illness, drugs that can help slow or cure the disease often put a financial strain on even the best insurance coverage.
The Affordable Care Act sets annual limits on the amount that people will owe out of pocket for prescription drugs starting in 2014. But sick people in some plans won't get relief until the following year because the federal government is giving some health plans extra time to comply.
"People living with multiple sclerosis and other chronic illnesses have been counting on this annual out-of-pocket limit coming, and now that may not happen in 2014," says Bari Talente, executive vice president of advocacy at the National Multiple Sclerosis Society.
Drugs to treat multiple sclerosis are frequently on an insurer's specialty drug tier and require a person to pay 25 to 30 percent of the cost rather than a fixed copayment, she says. In such cases, someone might spend roughly $700 out of pocket every month — $8,400 a year — on a drug to slow progression of the disease.
Under the law, the maximum amount that a consumer with single coverage will pay out of pocket for all medical care, including drugs, will generally be $6,350 in 2014. A family could pay as much as $12,700.
Those totals include copayments, coinsurance and deductibles, but not premiums, and they apply only to plans that are not grandfathered under the law.
But for those consumers whose health plans use more than one administrator to manage plan benefits — one for major medical claims and coverage, and another for pharmacy, for example — there may be one out-of-pocket cap for major medical and another for drugs, or no drug spending limits at all if a plan doesn't currently have a cap, as is typical.
The administration said in February that it recognized that the new annual out-of-pocket limits would need to be coordinated and might require new communication between service providers. That communication step is the reason the government gave the health plans extra time to comply.
But what's good for health plans isn't necessarily good for patients. "For those who are going to be hit with a double out-of-pocket maximum, it could be problematic," Talente says.
..
| Reactions: |
Personalised Therapy For Multiple Sclerosis Is Key Factor In Treatment Success
"Although the upcoming approval of new drugs against multiple sclerosis will offer a number of additional treatment options, it is important that we keep one thing in mind: The only way we can get this disease well under control is if we manage to provide personalised therapy tailored to the individual and to predict the effects and side-effects of a given drug. Unfortunately these efforts are still in the early stages of development," Prof Xavier Montalban (Multiple Sclerosis Centre of Catalonia, Spain) explained at the 23rd Meeting of the European Neurological Society (ENS) in Barcelona. More than 3,000 experts are currently gathered there to discuss latest developments in their field.
Prof Montalban urged that more pharmacologic research be done on biomarkers and that physicians cooperate more closely with patients to optimise therapy. Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system characterised by a high degree of heterogeneity. The clinical course of the disease and its degree of severity can vary widely from one individual to the next. It is now known that one and the same treatment can yield very different therapeutic results. Prof Montalban: "Despite an awareness of this problem, personalised therapy was not an issue for a long time, not least because of the lack of options. This situation could well change in the near future."
Highly effective drugs but a host of risks
We are seeing the end of a "one drug fits all" approach to multiple sclerosis therapy, said Prof Montalban. "Myriad new treatment options are becoming established right now. There is a well-founded hope that we will be able to help people suffering from MS more effectively and more quickly in future. We were familiar with this disease for 120 years without being able to treat it. For 15 years, drugs have been available without noteworthy side-effects but limited in their effectiveness. In the meantime a number of highly effective drugs have been put on the market. However, they involve risks ranging from hair loss and bradycardia to progressive multifocal leukoencephalopathy (PML). PML is a dangerous viral infection caused by the immune-suppressive effect of some drugs and can have fatal consequences. Prof Montalban: "In the meantime a test has been developed for determining the probability of patients to develop PML. This is a welcome step in the right direction. The genetic causes of the varying effectiveness of individual types of drugs are becoming increasingly clear." Interferon ?, the first disease-modifying drug that was approved, is effective on 20 to 55% of patients depending on the criteria applied. This fact has led science to make great efforts to find biomarkers that reliably indicate successful treatment and side-effects. Prof Montalban: "Right now we are at 100 possible biomarkers without a clear tendency. This shows how complex MS research is and how far we still have to go to achieve personalised medicine."
Danger of changing or stopping therapy
Under certain circumstances, more pharmacogenetic findings could enable experts to predict the consequences of switching therapies. The medical field remains in the dark on many aspects of this issue too, to the detriment of those affected. A Catalonian study presented at the ENS Meeting shows how problematic it can be to switch therapies. After five years suffering from MS, the seven study participants were medicated with the highly effective disease-modifying drug natalizumab because the previous treatment had failed. Their state of health remained stable for the average period of about 2.5 years they took this substance. They then had to switch to other weaker drugs for reasons varying from PML risk to pregnancy and allergic reactions. Despite the alternative medication, the patients' neurological state deteriorated quickly. After about three months, four of the seven subjects exhibited new lesions and two of the seven were even found to have sustained 40 new injuries to the central nervous system. A mere eleven months later, all patients had 40 to 70 new lesions. Prof Montalban: "When patients stop taking drugs like natalizumab, they can suffer disastrous relapses with a more aggressive disease than before. It is therefore urgent that we devise strategies to ensure greater continuity. This task extends beyond pharmacogenetics and requires a holistic approach to treatment."
New treatment guidelines take individual factors into account
Evidence-based treatment guidelines on MS therapy are now being thoroughly updated in a project under Prof Montalban's aegis and with the support of numerous national societies in this field. This revision takes account not only of the many pharmacological innovations such as oral therapies or drugs based on monoclonal antibodies. It also puts special emphasis on the many individual factors that personalise a therapy and make it more successful. These factors include thoroughly advising and informing the patients before treatment begins so they can decide on a therapy option and take part in carrying it out. To this end, the new guidelines also provide informational material for patients. Prof Montalban: "Initially, very fundamental questions have to be clarified: What do patients consider a successful therapy to be? What would they rather accept in this therapeutic tightrope walk: severe side-effects or early disablement? Are women planning to have children?" The decisive factor after that is to monitor and if need be, adapt the successful therapy. Prof Montalban: "To be successful, each therapy decision must be made in close consultation with the patients. Today, a patient-centred approach is more possible than ever before. That is because MS breaks out mostly in young adults aged 20 to 40. As a general rule, this group is digitally competent and can use the Internet to keep in constant contact with the physicians treating them. The extensive involvement of the patients is especially important with MS to increase compliance." Prof Montalban hopes the new guidelines will be implemented quickly and create greater awareness for personalised therapy options amongst general practitioners and neurologists.
The source for the above article is Medical News Today
..
REMAIN up to date with MS News and Education
| Reactions: |
Tuesday, June 11, 2013
Big Multiple Sclerosis Breakthrough Reduced 50-75% of bad immune system activity while leaving a normal immune system
JUNE 10, 2013
(MS) patients showed the therapy was safe and dramatically reduced patients’ immune systems’ reactivity to myelin by 50 to 75 percent, according to new Northwestern Medicine research.
In MS, the immune system attacks and destroys myelin, the insulating layer that forms around nerves in the spinal cord, brain and optic nerve. When the insulation is destroyed, electrical signals can’t be effectively conducted, resulting in symptoms that range from mild limb numbness to paralysis or blindness.
The human trial is the translation of more than 30 years of preclinical research in Miller's lab.
In the trial, the MS patients’ own specially processed white blood cells were used to stealthily deliver billions of myelin antigens into their bodies so their immune systems would recognize them as harmless and develop tolerance to them.
Current therapies for MS suppress the entire immune system, making patients more susceptible to everyday infections and higher rates of cancer.
While the trial’s nine patients -- who were treated in Hamburg, Germany -- were too few to statistically determine the treatment’s ability to prevent the progression of MS, the study did show patients who received the highest dose of white blood cells had the greatest reduction in myelin reactivity.
The primary aim of the study was to demonstrate the treatment’s safety and tolerability. It showed the intravenous injection of up to 3 billion white blood cells with myelin antigens caused no adverse affects in MS patients. Most importantly, it did not reactivate the patients’ disease and did not affect their healthy immunity to real pathogens.
As part of the study, researchers tested patients’ immunity to tetanus because all had received tetanus shots in their lifetime. One month after the treatment, their immune responses to tetanus remained strong, showing the treatment’s immune effect was specific only to myelin.
Continue Reading
..
REMAIN up to date with MS News and Education
| Reactions: |
Physician Overcomes Multiple Sclerosis; Inspires Others - a Patient's story

..
| Reactions: |